Tearsheet

Penumbra (PEN)

Market Price (4/12/2026): $329.82 | Market Cap: $12.9 Bil
Sector: Health Care | Industry: Health Care Equipment

Penumbra (PEN)

Market Price (4/12/2026): $329.82
Market Cap: $12.9 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12%

Low stock price volatility
Vol 12M is 37%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Geriatric Care.

Weak multi-year price returns
3Y Excs Rtn is -49%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 63x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x, P/EPrice/Earnings or Price/(Net Income) is 73x

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.6%

Key risks
PEN key risks include [1] significant litigation and regulatory fallout from the Class I recall of its Jet 7 catheter linked to patient deaths, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12%
1	Low stock price volatility Vol 12M is 37%
2	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Geriatric Care.
3	Weak multi-year price returns 3Y Excs Rtn is -49%
4	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 63x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x, P/EPrice/Earnings or Price/(Net Income) is 73x
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.6%
6	Key risks PEN key risks include [1] significant litigation and regulatory fallout from the Class I recall of its Jet 7 catheter linked to patient deaths, Show more.

Valuation, Metrics & Events

	4/12/26	2025	2024	2023	2022
Share Price CYE	$329.82	$267.41	$223.18	$278.69	$222.13
Market Cap CYE ($ Bil)	12.9	10.3	8.6	10.6	8.4
Total Debt ($ Bil)	0.2	0.2	0.2	0.2	0.2
Total Cash ($ Bil)	0.5	0.4	0.3	0.2	0.2
Enterprise Value ($ Bil)	12.6	10.5	8.8	10.8	8.6
Valuation Ratios
P/S TTM	9.2	8.3	7.9	12.0	10.7
P/EBIT TTM	62.6	200.5	98.9	601.4	-320.7
P/E TTM	72.7	244.2	92.5	1,642.1	-1,291.9
P/FCF TTM	73.9	68.6	82.0	-189.2	-2,997.3
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/12/26	2025	2024
Share Price CYE	$329.82	$267.41	$223.18
Market Cap CYE ($ Bil)	12.9	10.3	8.6
Total Debt ($ Bil)	0.2	0.2	0.2
Total Cash ($ Bil)	0.5	0.4	0.3
Enterprise Value ($ Bil)	12.6	10.5	8.8
Valuation Ratios
P/S TTM	9.2	8.3	7.9
P/EBIT TTM	62.6	200.5	98.9
P/E TTM	72.7	244.2	92.5
P/FCF TTM	73.9	68.6	82.0
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	PEN	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	1.4
Rev Chg Q	22.1%	7.5%
Rev Chg LTM	17.5%	6.8%
Rev Chg 3Y Avg	18.4%	5.7%
PROFITABILITY	FAIR
Op Inc LTM ($ Bil)	0.2
CFO LTM ($ Bil)	0.2
Net Inc LTM ($ Bil)	0.2
Op Mgn LTM	13.5%	18.6%
CFO/Rev LTM	17.0%	20.6%
Net Inc Mgn	12.7%	12.8%
VALUATION	VERY HIGH
P/S	9.2	3.2
P/CFO	54.2	15.4
P/FCF	73.9	19.8
P/E	72.7	24.1
STABILITY	VERY GOOD
Debt/Equity	0.02	0.21
Cash/Assets	0.30	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Employees	4500	12312024	Link
Global Market Presence	Over 100 countries	11062025	Link
Medical Pipeline Products	6	11082025	Link
Arterial Procedures Market Share (Forecasted)	46% in 2024	6082023	Link
Deep Vein Thrombosis Procedures Market Share (Forecasted)	42% in 2024	6082023	Link
Pulmonary Embolism Procedures Market Share (Forecasted)	39% in 2024	6082023	Link
Patent Portfolio	Penumbra maintains a robust patent portfolio for its core technologies, including its computer-assisted vacuum thrombectomy (CAVT) products.	11052025	Link

Upcoming
4/22/2026	Earnings Release	Rev: $371 Mil (E) EPS: $1.11 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Penumbra (PEN) stock has gained about 5% since 12/31/2025 because of the following key factors:

1. Acquisition Announcement by Boston Scientific.

Penumbra's stock experienced a significant surge following the announcement on January 14, 2026, that Boston Scientific would acquire the company in a cash and stock transaction valued at $374 per share, representing an enterprise value of approximately $14.5 billion. This offer price represented a substantial premium, driving investor confidence and the stock's upward trend. The transaction is slated for completion in 2026, pending stockholder approval and other customary closing conditions.

2. Robust Q4 2025 Earnings Beat.

The company reported strong financial results for the fourth quarter of 2025, with adjusted earnings per share (EPS) of $1.18, surpassing analysts' expectations of $1.12 by 5.36%. Additionally, quarterly revenue increased by 22.2% year-over-year to $385.39 million, exceeding the consensus estimate of $367.18 million. This strong performance was further supported by a 123 basis point expansion in gross margin, reaching 68%.

Show more

Stock Movement Drivers

Fundamental Drivers

The 6.1% change in PEN stock from 12/31/2025 to 4/11/2026 was primarily driven by a 5.2% change in the company's Total Revenues ($ Mil).

(LTM values as of)	12312025	4112026	Change
Stock Price ($)	310.91	329.77	6.1%
Change Contribution By:
Total Revenues ($ Mil)	1,334	1,404	5.2%
Net Income Margin (%)	12.3%	12.7%	2.9%
P/E Multiple	74.1	72.7	-1.8%
Shares Outstanding (Mil)	39	39	-0.3%
Cumulative Contribution			6.1%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/11/2026

	Return	Correlation
PEN	6.1%
Market (SPY)	-5.4%	7.0%
Sector (XLV)	-4.8%	-2.2%

Fundamental Drivers

The 30.2% change in PEN stock from 9/30/2025 to 4/11/2026 was primarily driven by a 9.7% change in the company's Net Income Margin (%).

(LTM values as of)	9302025	4112026	Change
Stock Price ($)	253.32	329.77	30.2%
Change Contribution By:
Total Revenues ($ Mil)	1,280	1,404	9.6%
Net Income Margin (%)	11.5%	12.7%	9.7%
P/E Multiple	66.6	72.7	9.2%
Shares Outstanding (Mil)	39	39	-0.9%
Cumulative Contribution			30.2%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/11/2026

	Return	Correlation
PEN	30.2%
Market (SPY)	-2.9%	-1.2%
Sector (XLV)	6.3%	11.3%

Fundamental Drivers

The 23.3% change in PEN stock from 3/31/2025 to 4/11/2026 was primarily driven by a 979.2% change in the company's Net Income Margin (%).

(LTM values as of)	3312025	4112026	Change
Stock Price ($)	267.41	329.77	23.3%
Change Contribution By:
Total Revenues ($ Mil)	1,195	1,404	17.5%
Net Income Margin (%)	1.2%	12.7%	979.2%
P/E Multiple	733.1	72.7	-90.1%
Shares Outstanding (Mil)	38	39	-2.0%
Cumulative Contribution			23.3%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/11/2026

	Return	Correlation
PEN	23.3%
Market (SPY)	16.3%	26.4%
Sector (XLV)	2.3%	26.4%

Fundamental Drivers

The 18.3% change in PEN stock from 3/31/2023 to 4/11/2026 was primarily driven by a 65.7% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4112026	Change
Stock Price ($)	278.69	329.77	18.3%
Change Contribution By:
Total Revenues ($ Mil)	847	1,404	65.7%
P/S Multiple	12.5	9.2	-26.4%
Shares Outstanding (Mil)	38	39	-3.0%
Cumulative Contribution			18.3%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/11/2026

	Return	Correlation
PEN	18.3%
Market (SPY)	63.3%	26.4%
Sector (XLV)	19.1%	27.2%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
PEN Return	64%	-23%	13%	-6%	31%	6%	88%
Peers Return	8%	-4%	12%	18%	19%	-7%	51%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
PEN Win Rate	58%	50%	67%	33%	50%	50%
Peers Win Rate	52%	52%	54%	58%	62%	44%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
PEN Max Drawdown	0%	-60%	-18%	-35%	-5%	-3%
Peers Max Drawdown	-7%	-19%	-7%	-4%	-2%	-13%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: SYK, MDT, JNJ, BSX. See PEN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	PEN	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-62.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	167.6%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	327 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-35.9%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	55.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	55 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-31.7%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	46.3%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	172 days	120 days

Compare to SYK, MDT, JNJ, BSX

In The Past

Penumbra's stock fell -62.6% during the 2022 Inflation Shock from a high on 4/28/2021. A -62.6% loss requires a 167.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Penumbra (PEN)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

AI Analysis | Feedback

Medtronic for neurovascular and peripheral vascular medical devices.

AI Analysis | Feedback

Aspiration-based Thrombectomy Systems: Devices like the Penumbra System and Indigo System used for mechanical thrombectomy to remove blood clots from neurovascular and peripheral vessels.
Neurovascular Embolization Coiling Systems: Systems such as Penumbra Coil 400 designed to treat aneurysms and other neurovascular lesions.
Neurovascular Access Systems: Devices like Neuron and BENCHMARK that provide intracranial access for various neurovascular therapies.
Neurosurgical Aspiration Tools: The Artemis Neuro Evacuation Device for removing tissue and fluids in neurosurgery.
Peripheral Embolization Devices: Detachable coils (e.g., Ruby Coil) and occlusion devices (e.g., POD) for blocking blood flow in peripheral vessels.
Immersive Therapeutics: The Real Immersive System, which uses computer-based technologies to promote health, motor function, and cognition.

AI Analysis | Feedback

Penumbra (PEN) sells primarily to other companies rather than individuals. As a designer, developer, manufacturer, and marketer of specialized medical devices, its major customers are healthcare institutions such as hospitals, surgical centers, and specialized clinics (e.g., those performing neurovascular and peripheral interventions) that utilize its advanced medical technologies.

The provided company description indicates that Penumbra sells its products through direct sales organizations and distributors, who then supply these medical devices to the aforementioned healthcare providers. However, the background information does not list the names of specific customer companies or distributors.

AI Analysis | Feedback

null

AI Analysis | Feedback

Adam Elsesser, Chairman and Chief Executive Officer

Adam Elsesser co-founded Penumbra, Inc. in 2004 and has served as its Chief Executive Officer and a director since its inception, and as Chairman since January 2015. Before co-founding Penumbra, he led SMART Therapeutics, Inc., a medical device company focused on neuro-intervention, as its Chief Executive Officer from 2000 to 2002. Following SMART Therapeutics' acquisition by Boston Scientific Corporation, he served as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Prior to his work in the medical device industry, Mr. Elsesser was a partner in the law firm of Shartsis Friese LLP.

Maggie Yuen, Chief Financial Officer

Maggie Yuen manages the financial strategy that supports Penumbra, Inc.'s aggressive research and development spending and market expansion. She is listed as the Chief Financial Officer on the company's leadership page.

Arani Bose, M.D., Co-Founder, Chief Innovator and Director

Dr. Arani Bose co-founded Penumbra, Inc. in 2004 and has been its Chief Innovator since 2004. He previously served as Chief Medical Officer and Chairman of Penumbra, Inc. from 2005 until 2015. Dr. Bose also founded Smart Therapeutics, Inc., where he developed neurovascular stents, and served as its Chairman. He was an Assistant Professor of Radiology and Neurology at the New York University School of Medicine.

Shruthi Narayan, President

Shruthi Narayan was promoted to President in September 2025, where she oversees the company's global operations and growth initiatives.

James F. Benenati, M.D., FSIR, Chief Medical Officer

Dr. James F. Benenati joined Penumbra, Inc. as Chief Medical Officer in September 2020. In this role, he contributes to clinical and medical affairs strategies and advises on global commercialization and market development activities. Prior to joining Penumbra, he practiced interventional radiology at the Miami Cardiac & Vascular Institute for over 30 years. He also served as the Director of the Fellowship Program and Medical Director of the Non-Invasive Vascular Laboratory at the institute.

AI Analysis | Feedback

Here are the key risks to Penumbra's business:

1. Regulatory and Product Liability Risks

As a medical device company, Penumbra operates in a highly regulated environment, subject to stringent domestic and international medical device regulations. Non-compliance, unforeseen issues with product safety or efficacy, or the need to meet evolving global regulatory standards (such as the EU MDR) can impede product approvals, hinder development and manufacturing activities, and result in costly product recalls or significant legal liabilities. The company has faced past allegations of product design defects, such as with its Jet 7 Xtra Flex catheter, which led to a voluntary recall and associated legal scrutiny, highlighting the tangible nature of this risk.

2. Intense Competition and Technological Obsolescence

Penumbra operates in a highly competitive medical device market characterized by rapid technological advancements and short product life cycles. The company faces significant competition from larger, well-capitalized players with extensive resources and established distribution networks, including companies like Boston Scientific, Medtronic, and Stryker. To maintain its market position and avoid technological obsolescence, Penumbra must continuously innovate and invest significantly in research and development. Failure to successfully develop and commercialize new products or to effectively compete against superior or more cost-effective technologies introduced by rivals could adversely affect its market share and financial performance.

3. Reimbursement Landscape Changes

The demand for Penumbra's medical devices is significantly influenced by the ability of healthcare providers to obtain adequate reimbursement for procedures utilizing these products. Reimbursement levels vary substantially across different countries and regions, originating from government-sponsored and private health insurance plans. Changes in healthcare policies, shifts in private insurance coverage decisions, or requirements for additional clinical data before or after recognizing coverage and reimbursement for Penumbra's products could negatively impact their adoption and sales.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here are the addressable market sizes for Penumbra's main products and services:

Neurovascular Thrombectomy Systems (for ischemic stroke):
- The global neurothrombectomy devices market size was estimated at USD 825.92 million in 2025 and is predicted to reach approximately USD 1,494.32 million by 2034. North America accounted for 38.12% of the neurovascular thrombectomy devices market revenue in 2025.
- Another source reported the global neurovascular thrombectomy devices market size at USD 3.00 billion in 2024, projected to reach USD 5.00 billion by 2032.
Neurovascular Embolization Coiling Systems (for aneurysms and other neurovascular lesions):
- The global neurovascular embolization market was valued at USD 1.4 billion in 2022 and is estimated to reach USD 2.5 billion by 2032. The U.S. neurovascular embolization market accounted for USD 503 million in 2022.
- The global neuroendovascular coil market was estimated at USD 1.22 billion in 2024 and is expected to reach USD 1.98 billion by 2030. The USA neuroendovascular coil market reached USD 0.46 billion in 2024.
- The global intracranial aneurysm market was valued at USD 1.74 billion in 2025 and is projected to grow to USD 2.95 billion by 2034. Endovascular coiling, a treatment type, accounted for 66.7% market share in 2025 for the intracranial aneurysm market and is expected to exceed USD 2.7 billion by 2035. The U.S. intracranial aneurysm market was USD 637.8 million in 2025.
Peripheral Aspiration-Based Thrombectomy Systems and Peripheral Embolization Devices:
- The global peripheral thrombectomy devices market size was valued at USD 684.99 million in 2025 and is expected to reach USD 1,134.50 million by 2033. The U.S. peripheral vascular thrombectomy devices market captured 42% of the revenue share in 2025 within North America.
- The global peripheral embolization devices market size was valued at USD 11.50 billion in 2022 and is expected to reach USD 6.10 billion by 2030, growing at a CAGR of 11.50%. Another report states the peripheral embolization device market was valued at USD 696.45 million in 2025 and is expected to increase to USD 1,118.35 million by 2032. North America dominates this market.
Immersive Computer-Based Technologies and Immersive Therapeutics (Real Immersive System):
- The global digital therapeutics market size was estimated at USD 7.88 billion in 2024 and is expected to reach approximately USD 56.76 billion by 2034. North America contributed the largest market share of 44.03% in 2023.
- The global immersive technologies market size was valued at USD 53.29 billion in 2025 and is projected to grow to USD 500.27 billion by 2034. Healthcare and life sciences represent nearly 14% of this market share.
- The Global Immersive Technology in Healthcare Market is projected to grow from USD 4.21 billion in 2025 to USD 12.48 billion by 2031.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Penumbra (PEN)

Penumbra (PEN) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and product advancements:

Expansion and Innovation in Computer Assisted Vacuum Thrombectomy (CAVT) Portfolio

Penumbra expects significant growth from its expanding portfolio of Computer Assisted Vacuum Thrombectomy (CAVT) products. Recent and anticipated product launches, such as Lightning Bolt 16 and Lightning Flash 3.0, have received FDA clearance and are designed to enhance clot detection and removal. Furthermore, the Thunderbolt system, currently in the final stages of FDA review, is expected to stimulate the U.S. market, especially for stroke treatment. The company plans to launch multiple new CAVT products in the United States, targeting market share gains and growth across deep vein thrombosis, pulmonary embolism, and arterial applications.
International Market Expansion

The company is strategically focused on materially increasing its international revenues and profitability over the next three years. This includes expanding its presence, particularly in Europe, by introducing advanced thrombectomy products, including its first-generation computer-aided devices, to global teams. Penumbra anticipates double-digit growth in its international business, with expected alleviation of China-specific headwinds by early next year.
Growing Adoption of U.S. Thrombectomy and Embolization Products

Penumbra foresees continued strong demand and increased market penetration for its thrombectomy and embolization products in the U.S. This growth is being fueled by robust demand for its U.S. VTE (Venous Thromboembolism) franchise and embolization solutions. Strategic investments, such as the dedicated expansion of the U.S. Peripheral Embolization sales team and the successful launch of products like Ruby XL, have already resulted in significant sequential growth in embolization revenue.
Positive Clinical Data Driving Product Adoption

The outcomes from landmark clinical trials, such as the STORM-PE randomized controlled trial, are crucial for accelerating product adoption. The STORM-PE results demonstrated that CAVT, combined with anticoagulation, significantly improved functional outcomes for patients with pulmonary embolism. These findings are expected to build physician confidence and lead to a more rapid integration of Penumbra's advanced thrombectomy systems into hospital protocols.

AI Analysis | Feedback

Share Repurchases

Penumbra's Board of Directors authorized a share repurchase program of up to $200 million on August 5, 2024, set to expire on July 31, 2025.
As part of this authorization, Penumbra entered into an accelerated share repurchase agreement (ASR) on August 12, 2024, to repurchase $100 million of its common stock.
An initial delivery of approximately 474,000 shares of Penumbra's common stock was received on August 13, 2024, with the final settlement of the ASR expected in the third quarter of 2024.

Inbound Investments

Boston Scientific Corporation announced in January 2026 its definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion to $15 billion in a cash and stock deal.

Capital Expenditures

Penumbra's capital expenditures were approximately $19.46 million for the last 12 months as of December 31, 2024.
Annual capital expenditures were $13 million in 2023, $14 million in 2024, and $5.47 million in 2025.
Strategic capital investments have been directed towards establishing facilities, such as the Costa Rica facility, to support global market expansion.

Interactive Breakdown

null

null

Better Bets vs. Penumbra (PEN)

INDUSTRY: Health Care Equipment

Higher Rev Chg 3Y Avg | Lower P/S (Values for PEN: 18.4% | 9.2x)

PODD (27.6% | 5.1x)

Insulet

GMED (43.5% | 4.1x)

Globus Medical

TMDX (92.8% | 6.4x)

TransMedics

INSP (31.8% | 1.7x)

Inspire Medical Systems

UFPT (19.6% | 2.6x)

UFP Technologies

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for PEN: 18.4% | 68.3x)

PODD (27.6% | 29.2x)

Insulet

GMED (43.5% | 22.6x)

Globus Medical

TMDX (92.8% | 35.9x)

TransMedics

INSP (31.8% | 30.7x)

Inspire Medical Systems

UFPT (19.6% | 16.7x)

UFP Technologies

Higher Rev Chg LTM (Value for PEN: 17.5%)

TMDX (37.1%)

TransMedics

GKOS (32.3%)

Glaukos

PODD (30.7%)

Insulet

ISRG (20.5%)

Intuitive Surgical

BSX (19.9%)

Boston Scientific

Higher Rev Chg 3Y Avg (Value for PEN: 18.4%)

TMDX (92.8%)

TransMedics

GMED (43.5%)

Globus Medical

INSP (31.8%)

Inspire Medical Systems

PODD (27.6%)

Insulet

GKOS (21.8%)

Glaukos

Higher Op Mgn LTM (Value for PEN: 13.5%)

ISRG (29.3%)

Intuitive Surgical

SYK (20.1%)

Stryker

BSX (19.8%)

Boston Scientific

MDT (18.6%)

Medtronic

ABT (18.2%)

Abbott Laboratories

Higher CFO/Rev LTM (Value for PEN: 17.0%)

ISRG (30.1%)

Intuitive Surgical

BSX (22.6%)

Boston Scientific

ABT (21.6%)

Abbott Laboratories

MDT (20.5%)

Medtronic

SYK (20.1%)

Stryker

Higher FCF/Rev LTM (Value for PEN: 12.5%)

ISRG (24.7%)

Intuitive Surgical

SYK (17.1%)

Stryker

BSX (17.0%)

Boston Scientific

ABT (16.7%)

Abbott Laboratories

MDT (15.2%)

Medtronic

Higher Total Yield (Value for PEN: 1.4%)

MDT (7.4%)

Medtronic

ABT (6.1%)

Abbott Laboratories

SYK (3.5%)

Stryker

BSX (3.2%)

Boston Scientific

ISRG (1.8%)

Intuitive Surgical

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for PEN: 18.4% | 9.2x)

MEDP (20.3% | 5.5x)

Medpace

PODD (27.6% | 5.1x)

Insulet

NBIX (24.3% | 4.5x)

Neurocrine Biosciences

GMED (43.5% | 4.1x)

Globus Medical

ENSG (18.7% | 2.3x)

Ensign

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for PEN: 18.4% | 68.3x)

LLY (32.1% | 28.3x)

Eli Lilly

MEDP (20.3% | 26.1x)

Medpace

PODD (27.6% | 29.2x)

Insulet

NBIX (24.3% | 20.3x)

Neurocrine Biosciences

GMED (43.5% | 22.6x)

Globus Medical

Higher Rev Chg LTM (Value for PEN: 17.5%)

INSM (66.7%)

Insmed

ALNY (65.2%)

Alnylam Pharmaceuticals

LLY (44.7%)

Eli Lilly

ISRG (20.5%)

Intuitive Surgical

BSX (19.9%)

Boston Scientific

Higher Rev Chg 3Y Avg (Value for PEN: 18.4%)

BBIO (774.5%)

BridgeBio Pharma

ALNY (54.8%)

Alnylam Pharmaceuticals

NTRA (41.5%)

Natera

INSM (36.8%)

Insmed

LLY (32.1%)

Eli Lilly

Higher Op Mgn LTM (Value for PEN: 13.5%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

JNJ (27.2%)

Johnson & Johnson

AMGN (24.7%)

Amgen

Higher CFO/Rev LTM (Value for PEN: 17.0%)

ABBV (31.1%)

AbbVie

AMGN (27.1%)

Amgen

JNJ (26.0%)

Johnson & Johnson

LLY (25.8%)

Eli Lilly

MRK (25.3%)

Merck

Higher FCF/Rev LTM (Value for PEN: 12.5%)

ABBV (29.1%)

AbbVie

AMGN (22.0%)

Amgen

JNJ (20.5%)

Johnson & Johnson

MRK (19.0%)

Merck

TMO (14.1%)

Thermo Fisher Scientific

Higher Total Yield (Value for PEN: 1.4%)

MRK (8.8%)

Merck

UNH (7.2%)

UnitedHealth

JNJ (6.8%)

Johnson & Johnson

ABBV (4.3%)

AbbVie

LLY (3.1%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for PEN: 18.4% | 9.2x)

META (19.9% | 7.9x)

Meta Platforms

BRK-B (27.0% | 2.5x)

Berkshire Hathaway

MU (45.3% | 8.1x)

Micron Technology

APH (24.1% | 7.5x)

Amphenol

NEM (26.2% | 5.8x)

Newmont

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for PEN: 18.4% | 68.3x)

NVDA (101.8% | 35.2x)

NVIDIA

AVGO (26.2% | 62.2x)

Broadcom

META (19.9% | 19.1x)

Meta Platforms

MU (45.3% | 16.8x)

Micron Technology

ANET (27.3% | 48.1x)

Arista Networks

Higher Rev Chg LTM (Value for PEN: 17.5%)

MU (85.5%)

Micron Technology

NVDA (65.5%)

NVIDIA

AMD (34.3%)

Advanced Micro Devices

AVGO (25.2%)

Broadcom

META (22.2%)

Meta Platforms

Higher Rev Chg 3Y Avg (Value for PEN: 18.4%)

NVDA (101.8%)

NVIDIA

MU (45.3%)

Micron Technology

BRK-B (27.0%)

Berkshire Hathaway

AVGO (26.2%)

Broadcom

META (19.9%)

Meta Platforms

Higher Op Mgn LTM (Value for PEN: 13.5%)

NVDA (60.4%)

NVIDIA

MSFT (46.7%)

Microsoft

AVGO (41.5%)

Broadcom

AAPL (32.4%)

Apple

GOOGL (32.0%)

Alphabet

Higher CFO/Rev LTM (Value for PEN: 17.0%)

MSFT (52.5%)

Microsoft

NVDA (47.6%)

NVIDIA

GOOGL (40.9%)

Alphabet

AAPL (31.1%)

Apple

AMZN (19.5%)

Amazon.com

Higher FCF/Rev LTM (Value for PEN: 12.5%)

NVDA (44.8%)

NVIDIA

AVGO (42.3%)

Broadcom

AAPL (28.3%)

Apple

MSFT (25.3%)

Microsoft

GOOGL (18.2%)

Alphabet

Higher Total Yield (Value for PEN: 1.4%)

MSFT (5.2%)

Microsoft

GOOGL (3.7%)

Alphabet

AAPL (3.5%)

Apple

AMZN (3.0%)

Amazon.com

NVDA (2.6%)

NVIDIA

Best Bets in Health Care

What You Pay

P/EBIT (Value for PEN: 62.6x)

RPRX (12.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.0x)

Veeva Systems

HALO (16.5x)

Halozyme Therapeutics

UTHR (14.3x)

United Therapeutics

CPRX (11.9x)

Catalyst Pharmaceuticals

BMY (10.6x)

Bristol-Myers Squibb

RMD (18.1x)

ResMed

AMGN (16.1x)

Amgen

PBH (8.8x)

Prestige Consumer Healthcare

P/E (Value for PEN: 72.7x)

RPRX (26.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.3x)

Veeva Systems

HALO (25.2x)

Halozyme Therapeutics

UTHR (18.6x)

United Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

BMY (16.9x)

Bristol-Myers Squibb

RMD (22.5x)

ResMed

AMGN (24.5x)

Amgen

PBH (14.5x)

Prestige Consumer Healthcare

What You Get

Rev Chg 3Y Avg (Value for PEN: 18.4%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

AMGN (11.9%)

Amgen

PBH (-0.1%)

Prestige Consumer Healthcare

Rev Chg LTM (Value for PEN: 17.5%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

AMGN (10.0%)

Amgen

PBH (-1.3%)

Prestige Consumer Healthcare

Rev Chg Q (Value for PEN: 22.1%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

AMGN (8.6%)

Amgen

PBH (-2.4%)

Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for PEN: 10.9%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

AMGN (26.4%)

Amgen

PBH (22.3%)

Prestige Consumer Healthcare

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	PEN Stock Surges 19% With A 7-day Winning Spree On Boston Scientific Bid	01/24/2026
2	Penumbra Stock (+12%): Boston Scientific Takeout Bid Validates Growth Story	01/16/2026
3	Penumbra Earnings Notes	12/28/2026
4	Penumbra Stock Jump Looks Great, But How Secure Is That Gain?	10/17/2025
5	Penumbra vs Meta Platforms: Which Is A Better Investment?	08/18/2025
6	Penumbra vs Eli Lilly: Which Is A Better Investment?	08/18/2025
7	Penumbra vs Boston Scientific: Which Is A Better Investment?	08/18/2025
8	How Does Penumbra Stock Stack Up Against Its Peers?	08/13/2025
9	ARTICLES
10	PEN Stock Surges 19% With A 6-day Winning Spree On Price Target Hikes	01/23/2026
11	Mid Cap Stocks Trading At 52-Week High	12/11/2025
12	Better Bet Than Artivion Stock: Pay Less To Get More From PEN, PODD	08/21/2025
13	Strong Revenue Trends And Better Prospects Make Penumbra Stock A Good Bet	05/23/2022
14	Down 16% In A Month, Will Penumbra Stock Rebound?	03/14/2022

	Title
0	DASHBOARDS
1	PEN Stock Surges 19% With A 7-day Winning Spree On Boston Scientific Bid
2	Penumbra Stock (+12%): Boston Scientific Takeout Bid Validates Growth Story
3	Penumbra Earnings Notes
4	Penumbra Stock Jump Looks Great, But How Secure Is That Gain?
5	Penumbra vs Meta Platforms: Which Is A Better Investment?
6	Penumbra vs Eli Lilly: Which Is A Better Investment?
7	Penumbra vs Boston Scientific: Which Is A Better Investment?
8	How Does Penumbra Stock Stack Up Against Its Peers?
9	ARTICLES
10	PEN Stock Surges 19% With A 6-day Winning Spree On Price Target Hikes
11	Mid Cap Stocks Trading At 52-Week High
12	Better Bet Than Artivion Stock: Pay Less To Get More From PEN, PODD
13	Strong Revenue Trends And Better Prospects Make Penumbra Stock A Good Bet
14	Down 16% In A Month, Will Penumbra Stock Rebound?

Trade Ideas

Select ideas related to PEN.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OGN	Organon	2.3	27.8%	23.5%
LWLG	Lightwave Logic	1.4	25.6%	227.2%
POET	POET Technologies	0.6	15.8%	11.2%
ALAB	Astera Labs	25.3	15.1%	-10.4%
MANE	Veradermics	1.4	14.7%	82.3%
TTMI	TTM Technologies	12.6	13.0%	76.1%
AAOI	Applied Optoelectronics	10.6	13.0%	332.0%
FBYD	Falcons Beyond Global	0.5	12.6%	-18.9%
TE	T1 Energy	0.8	12.2%	-29.8%
CRWV	CoreWeave	51.7	10.9%	42.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	3.5	-21.7%	126.6%
REPL	Replimune	0.4	-19.5%	-51.0%
AKAM	Akamai Technologies	13.2	-16.7%	4.7%
FICO	Fair Isaac	21.9	-14.0%	-45.4%
SEZL	Sezzle	2.0	-13.6%	-5.9%
NET	Cloudflare	58.6	-13.5%	-15.3%
DOCN	DigitalOcean	6.9	-13.3%	57.1%
SMPL	Simply Good Foods	1.0	-11.5%	-48.0%
EVMN	Evommune	0.8	-11.0%	49.0%
GH	Guardant Health	10.1	-9.8%	-23.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AEHR	Aehr Test Systems	2.1	58.9%	248.8%
CAR	Avis Budget	10.6	57.5%	133.7%
AAOI	Applied Optoelectronics	10.6	44.9%	332.0%
OGN	Organon	2.3	38.8%	23.5%
LWLG	Lightwave Logic	1.4	38.4%	227.2%
HUT	Hut 8	7.2	37.4%	43.9%
SLNO	Soleno Therapeutics	2.8	33.3%	13.7%
STAA	Staar Surgical	1.3	30.8%	14.5%
RIOT	Riot Platforms	5.8	29.1%	31.0%
CIFR	Cipher Digital	6.6	28.9%	12.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.4	-43.4%	-51.0%
FSLY	Fastly	3.5	-31.1%	126.6%
SMPL	Simply Good Foods	1.0	-26.3%	-48.0%
AKAM	Akamai Technologies	13.2	-22.6%	4.7%
GWRE	Guidewire Software	10.0	-21.8%	-41.3%
OKTA	Okta	11.2	-21.5%	-27.2%
HUBS	HubSpot	10.1	-21.4%	-52.1%
NET	Cloudflare	58.6	-21.1%	-15.3%
VRDN	Viridian Therapeutics	1.4	-20.6%	-52.0%
SNOW	Snowflake	41.5	-20.2%	-44.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1475.9%	-5.1%
CAR	Avis Budget	10.6	196.4%	133.7%
SATL	Satellogic	1.0	135.7%	292.0%
LWLG	Lightwave Logic	1.4	111.2%	227.2%
APLS	Apellis Pharmaceuticals	5.2	110.5%	62.4%
FBYD	Falcons Beyond Global	0.5	92.1%	-18.9%
FLY	Firefly Aerospace	6.0	82.2%	67.8%
KOD	Kodiak Sciences	2.3	75.7%	54.2%
KODK	Eastman Kodak	1.2	74.0%	42.9%
ORKA	Oruka Therapeutics	3.2	73.1%	96.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-49.0%	-57.8%
VRDN	Viridian Therapeutics	1.4	-47.8%	-52.0%
MAZE	Maze Therapeutics	1.2	-47.1%	-35.6%
BUR	Burford Capital	1.0	-47.0%	-51.1%
FRMI	Fermi	2.9	-43.9%	-39.1%
TE	T1 Energy	0.8	-42.4%	-29.8%
REPL	Replimune	0.4	-39.7%	-51.0%
ADMA	ADMA Biologics	2.3	-38.1%	-46.8%
FIG	Figma	9.3	-34.8%	-51.4%
BOBS	Bobs Discount Furniture	1.4	-34.7%	-34.8%

Peer Comparisons

Peers to compare with:

Financials

	PEN	SYK	MDT	JNJ	BSX	Median
Name	Penumbra	Stryker	Medtronic	Johnson .	Boston S.
Mkt Price	329.77	339.15	87.21	238.46	61.79	238.46
Mkt Cap	12.9	129.7	111.9	574.1	91.6	111.9
Rev LTM	1,404	25,116	35,483	94,193	20,075	25,116
Op Inc LTM	189	5,059	6,611	25,596	3,971	5,059
FCF LTM	175	4,283	5,410	19,313	3,404	4,283
FCF 3Y Avg	135	3,635	5,269	18,383	2,491	3,635
CFO LTM	239	5,044	7,285	24,530	4,534	5,044
CFO 3Y Avg	168	4,332	7,016	23,862	3,491	4,332

Growth & Margins

	PEN	SYK	MDT	JNJ	BSX	Median
Name	Penumbra	Stryker	Medtronic	Johnson .	Boston S.
Rev Chg LTM	17.5%	11.2%	6.9%	6.0%	19.9%	11.2%
Rev Chg 3Y Avg	18.4%	10.8%	4.9%	2.6%	16.6%	10.8%
Rev Chg Q	22.1%	11.4%	8.7%	9.1%	15.9%	11.4%
QoQ Delta Rev Chg LTM	5.2%	3.0%	2.1%	2.2%	3.7%	3.0%
Op Mgn LTM	13.5%	20.1%	18.6%	27.2%	19.8%	19.8%
Op Mgn 3Y Avg	9.8%	20.0%	18.5%	25.6%	18.2%	18.5%
QoQ Delta Op Mgn LTM	0.5%	0.5%	-0.7%	1.5%	0.6%	0.5%
CFO/Rev LTM	17.0%	20.1%	20.5%	26.0%	22.6%	20.5%
CFO/Rev 3Y Avg	13.4%	19.0%	20.8%	26.7%	20.2%	20.2%
FCF/Rev LTM	12.5%	17.1%	15.2%	20.5%	17.0%	17.0%
FCF/Rev 3Y Avg	10.9%	15.9%	15.7%	20.6%	14.3%	15.7%

Valuation

	PEN	SYK	MDT	JNJ	BSX	Median
Name	Penumbra	Stryker	Medtronic	Johnson .	Boston S.
Mkt Cap	12.9	129.7	111.9	574.1	91.6	111.9
P/S	9.2	5.2	3.2	6.1	4.6	5.2
P/EBIT	62.6	25.3	17.8	17.1	24.5	24.5
P/E	72.7	40.0	24.2	21.4	31.6	31.6
P/CFO	54.2	25.7	15.4	23.4	20.2	23.4
Total Yield	1.4%	3.5%	7.4%	6.8%	3.2%	3.5%
Dividend Yield	0.0%	1.0%	3.2%	2.2%	0.0%	1.0%
FCF Yield 3Y Avg	1.3%	2.8%	4.7%	4.6%	2.1%	2.8%
D/E	0.0	0.1	0.3	0.1	0.1	0.1
Net D/E	-0.0	0.1	0.2	0.0	0.1	0.1

Returns

	PEN	SYK	MDT	JNJ	BSX	Median
Name	Penumbra	Stryker	Medtronic	Johnson .	Boston S.
1M Rtn	-1.6%	0.8%	0.6%	-1.5%	-9.9%	-1.5%
3M Rtn	2.3%	-7.5%	-9.9%	17.3%	-36.7%	-7.5%
6M Rtn	26.6%	-6.5%	-7.2%	26.5%	-35.2%	-6.5%
12M Rtn	21.1%	-2.2%	8.5%	61.5%	-34.0%	8.5%
3Y Rtn	18.9%	20.4%	19.0%	59.1%	20.9%	20.4%
1M Excs Rtn	-2.5%	-2.3%	-1.8%	-2.5%	-11.9%	-2.5%
3M Excs Rtn	6.0%	-5.9%	-9.4%	18.0%	-35.7%	-5.9%
6M Excs Rtn	26.4%	-10.1%	-10.4%	26.2%	-37.1%	-10.1%
12M Excs Rtn	-7.9%	-35.3%	-26.9%	26.6%	-68.6%	-26.9%
3Y Excs Rtn	-48.8%	-44.6%	-45.3%	-1.7%	-42.8%	-44.6%

Comparison Analyses

	Title
0	How Does Penumbra Stock Stack Up Against Its Peers?
1	PEN Could Deliver 45% Returns And Outperform MASI
2	Penumbra vs. Stryker: With Return Forecast Of 87%, Penumbra Is A Better Bet
3	Penumbra vs. Gap: With Return Forecast Of 70%, Penumbra Is A Better Bet
4	Penumbra vs. Aspen Technology: With Return Forecast Of 83%, Penumbra Is A Better Bet
5	Penumbra vs. Paylocity Holding: With Return Forecast Of 83%, Penumbra Is A Better Bet
6	Penumbra vs. Alnylam Pharmaceuticals: With Return Forecast Of 83%-86%, Both Seem Like Good Bets
7	Penumbra vs. Hertz Global: Similar Market Cap, But Penumbra Is A Better Bet
8	Penumbra vs. Arrow Electronics: Similar Market Cap, But Penumbra Is A Better Bet
9	Penumbra vs. Knight Transportation: Similar Market Cap, Similar Bets

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	2/25/2026	2/25/2026	2/18/2025	2/22/2024	2/23/2023	2/22/2022	2/23/2021
Key Financials
Total Revenue	1,404	1,404	1,195	1,059	847	748	560
EBITDA	224	224	46	109	30	8	-26
Operating Income	189	189	86	92	6	-8	-39
Net Income	178	178	14	91	-2	5	-16
EPS	4.57	4.57	0.36	2.37	-0.05	0.14	-0.44
Growth Rates
Total Revenue Growth	17.5%	17.5%	12.9%	25.0%	13.3%	33.4%	2.4%
EBITDA Growth	386.9%	386.9%	-57.7%	262.6%	282.2%	130.1%	-146.8%
Operating Income Growth	119.5%	119.5%	-6.0%	1408.8%	181.1%	80.7%	-182.0%
Net Income Growth	1168.1%	1168.1%	-84.6%	4643.2%	-137.9%	133.7%	-132.4%
Margins
EBITDA Margin	16.0%	16.0%	3.8%	10.3%	3.5%	1.0%	-4.6%
Operating Income Margin	13.5%	13.5%	7.2%	8.7%	0.7%	-1.0%	-6.9%
Net Income Margin	12.7%	12.7%	1.2%	8.6%	-0.2%	0.7%	-2.8%
Cash & Debt
Total Cash	545	545	340	289	188	255	265
Total Debt	220	220	223	234	236	174	77
Net Debt / (Cash)	-325	-325	-117	-55	48	-81	-188
Cash Flows
Net Cash from Operations	239	239	168	97	-56	10	-33
Free Cash from Operations	175	175	147	82	-75	-12	-58
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	100	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	2/25/2026	11/5/2025	7/29/2025	4/23/2025	2/18/2025	10/30/2024	7/30/2024	5/7/2024	2/22/2024	11/2/2023	8/1/2023	5/2/2023
Key Financials Quarterly
Total Revenue	385	355	339	324	316	301	299	279	285	271	261	241
Ebitda	68	55	51	49	49	44	-70	23	46	21	27	15
Operating Income	59	49	41	40	43	35	-4	12	35	31	18	8
Net Income	47	46	45	39	34	30	-60	11	54	9	19	9
EPS	1.21	1.17	1.17	1.02	0.88	0.76	-1.55	0.28	1.41	0.24	0.49	0.22
Key Financials TTM
Total Revenue TTM	1,404	1,334	1,280	1,240	1,195	1,164	1,134	1,096	1,059	995	938	885
Ebitda TTM	224	205	194	73	46	43	19	116	108	73	64	43
Operating Income TTM	189	173	159	114	86	78	74	96	92	62	36	18
Net Income TTM	178	164	148	42	14	35	14	93	91	41	29	6
Growth Rates Quarterly
Total Revenue Growth	22.1%	17.8%	13.4%	16.3%	10.8%	11.1%	14.5%	15.4%	28.7%	26.8%	25.5%	18.4%
EBITDA Growth	39.5%	24.6%	173.2%	118.2%	7.5%	114.0%	-361.8%	54.6%	321.2%	77.4%	361.0%	768.0%
Operating Income Growth	38.5%	38.1%	1116.6%	233.4%	22.1%	14.7%	-122.4%	51.1%	624.8%	467.5%	12969.8%	297.9%
Net Income Growth	40.6%	55.3%	175.2%	256.5%	-37.9%	220.5%	-417.5%	28.5%	1298.5%	505.7%	614.2%	10738.0%
Margins Quarterly
EBITDA Margin	17.8%	15.5%	15.1%	15.2%	15.6%	14.7%	-23.3%	8.1%	16.0%	7.6%	10.2%	6.0%
Operating Income Margin	15.4%	13.8%	12.0%	12.4%	13.6%	11.7%	-1.3%	4.3%	12.3%	11.4%	6.8%	3.3%
Net Income Margin	12.3%	12.9%	13.3%	12.1%	10.7%	9.8%	-20.1%	3.9%	19.0%	3.4%	7.3%	3.5%
Cash & Debt
Total Cash	545	470	425	379	340	291	340	313	289	249	221	199
Total Debt	220	217	221	221	223	227	229	231	234	229	231	234
Net Debt / (Cash)	-325	-253	-204	-158	-117	-64	-111	-82	-55	-20	10	34
Cash Flows Quarterly
FCF from Operations	86	58	45	49	51	56	23	38	36	31	17	13
Cash Flows TTM
FCF from Operations TTM	239	203	201	179	168	154	128	122	97	62	19	-38
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	20.4%	18.7%	17.3%	15.1%	13.3%	10.4%	-1.3%	3.7%	14.2%	8.5%	6.9%	3.1%
Return on Invested Capital (ROIC) TTM
ROIC TTM	19.0%	16.7%	14.4%	10.1%	5.9%	7.7%	7.7%	9.8%	9.3%	5.1%	2.7%	0.7%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Thrombectomy	815	677	511
Embolization and Access	379	381	336
Neuro				339	293
Vascular				409	268
Total	1,195	1,059	847	748	560

Price Behavior

Price Behavior

Market Price	$329.77
Market Cap ($ Bil)	12.9
First Trading Date	09/18/2015
Distance from 52W High	-8.2%
	50 Days	200 Days
DMA Price	$338.52	$289.04
DMA Trend	up	up
Distance from DMA	-2.6%	14.1%
	3M	1YR
Volatility	30.7%	36.0%
Downside Capture	0.22	0.10
Upside Capture	81.60	37.96
Correlation (SPY)	4.9%	12.0%

PEN Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	0.10	0.03	0.18	-0.04	0.52	0.68
Up Beta	0.14	-0.17	-0.69	-0.08	0.77	0.86
Down Beta	-0.04	-0.17	-0.44	-0.61	0.37	0.35
Up Capture	13%	-3%	97%	64%	35%	43%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	9	18	29	60	116	364
Down Capture	29%	33%	41%	-14%	34%	92%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	13	24	34	66	135	385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with PEN
PEN	29.8%	36.7%	0.77	-
Sector ETF (XLV)	12.3%	16.8%	0.52	24.0%
Equity (SPY)	31.2%	17.3%	1.47	23.2%
Gold (GLD)	60.1%	27.8%	1.69	-1.8%
Commodities (DBC)	29.8%	16.6%	1.58	3.1%
Real Estate (VNQ)	21.3%	15.2%	1.07	19.9%
Bitcoin (BTCUSD)	-4.3%	43.7%	0.02	-0.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with PEN
PEN	3.8%	41.8%	0.21	-
Sector ETF (XLV)	6.3%	14.6%	0.25	37.7%
Equity (SPY)	11.1%	17.0%	0.50	41.1%
Gold (GLD)	22.1%	17.8%	1.02	7.0%
Commodities (DBC)	11.8%	18.8%	0.52	6.2%
Real Estate (VNQ)	3.7%	18.8%	0.10	35.2%
Bitcoin (BTCUSD)	4.3%	56.5%	0.30	17.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with PEN
PEN	21.7%	41.7%	0.61	-
Sector ETF (XLV)	9.8%	16.5%	0.48	41.1%
Equity (SPY)	13.8%	17.9%	0.66	42.8%
Gold (GLD)	14.2%	15.9%	0.74	6.4%
Commodities (DBC)	8.6%	17.6%	0.41	11.2%
Real Estate (VNQ)	5.1%	20.7%	0.22	33.8%
Bitcoin (BTCUSD)	67.6%	66.9%	1.07	9.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	2.4 Mil
Short Interest: % Change Since 3152026	18.3%
Average Daily Volume	0.7 Mil
Days-to-Cover Short Interest	3.7 days
Basic Shares Quantity	39.2 Mil
Short % of Basic Shares	6.2%

Returns Analyses

	Title
0	Penumbra Stock Jump Looks Great, But How Secure Is That Gain?
1	Penumbra Stock Return Comparison
2	[10/14/2021] Penumbra (PEN) Stock Price Forecast: AI Forecasts PEN Stock Price To Be Around $276 In A Month (Up 2.5%)
3	Penumbra (PEN) Stock Return: AI Predicts PEN Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
1/15/2026	11.8%	14.4%	8.3%
11/5/2025	17.3%	24.3%	30.7%
7/29/2025	11.9%	5.7%	17.5%
2/18/2025	12.0%	3.9%	3.1%
10/30/2024	8.3%	10.6%	15.5%
7/30/2024	-3.5%	-1.0%	15.8%
5/7/2024	-3.3%	-0.6%	-6.5%
2/22/2024	-9.3%	-10.6%	-14.4%
...
SUMMARY STATS
# Positive	11	11	12
# Negative	11	11	10
Median Positive	11.8%	10.6%	15.4%
Median Negative	-3.3%	-7.3%	-9.2%
Max Positive	17.3%	25.7%	40.5%
Max Negative	-9.7%	-19.0%	-16.2%

	Forward Returns
1/15/2026	11.8%	14.4%	8.3%
11/5/2025	17.3%	24.3%	30.7%
7/29/2025	11.9%	5.7%	17.5%
2/18/2025	12.0%	3.9%	3.1%
10/30/2024	8.3%	10.6%	15.5%
7/30/2024	-3.5%	-1.0%	15.8%
5/7/2024	-3.3%	-0.6%	-6.5%
2/22/2024	-9.3%	-10.6%	-14.4%
11/2/2023	-0.2%	-7.3%	15.3%
8/1/2023	-9.7%	-16.9%	-11.5%
2/23/2023	2.2%	-0.3%	4.9%
11/3/2022	6.7%	25.7%	39.6%
8/5/2022	16.6%	18.7%	15.3%
5/3/2022	-1.9%	-19.0%	-16.2%
2/22/2022	-5.8%	3.5%	-4.7%
11/3/2021	3.8%	-2.8%	-14.2%
8/9/2021	-2.0%	-4.1%	3.1%
5/4/2021	-5.4%	-8.4%	-11.2%
1/11/2021	4.3%	15.6%	40.5%
10/28/2020	13.5%	7.0%	-2.6%
8/3/2020	-0.9%	1.3%	-7.2%
5/7/2020	-2.9%	-8.3%	-3.4%
SUMMARY STATS
# Positive	11	11	12
# Negative	11	11	10
Median Positive	11.8%	10.6%	15.4%
Median Negative	-3.3%	-7.3%	-9.2%
Max Positive	17.3%	25.7%	40.5%
Max Negative	-9.7%	-19.0%	-16.2%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	02/25/2026	10-K
09/30/2025	11/05/2025	10-Q
06/30/2025	07/29/2025	10-Q
03/31/2025	04/23/2025	10-Q
12/31/2024	02/18/2025	10-K
09/30/2024	10/30/2024	10-Q
06/30/2024	07/30/2024	10-Q
03/31/2024	05/07/2024	10-Q
12/31/2023	02/22/2024	10-K
09/30/2023	11/02/2023	10-Q
06/30/2023	08/01/2023	10-Q
03/31/2023	05/02/2023	10-Q
12/31/2022	02/23/2023	10-K
09/30/2022	11/03/2022	10-Q
06/30/2022	08/05/2022	10-Q
03/31/2022	05/03/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/25/2026

null

Prior: Q3 2025 Earnings Reported 11/5/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2025 Total Revenue	1.38 Bil	1.38 Bil	1.38 Bil	1.1%		Raised	Guidance: 1.36 Bil for 2025
2025 Revenue Growth	15.0%	15.5%	16.0%	10.7%	1.5%	Raised	Guidance: 14.0% for 2025
2025 U.S. Thrombectomy Growth	20.0%	20.5%	21.0%	0	0	Affirmed	Guidance: 20.5% for 2025

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Wilder, Thomas		Direct	Sell	1062026	310.72	186			Form
2	Bose, Arani		LLC	Sell	12152025	308.82	15,000	4,632,292	79,818,099	Form
3	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	12092025	300.13	300	90,039	19,159,099	Form
4	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	12032025	294.94	600	176,966	18,916,497	Form
5	Grewal, Harpreet		Direct	Sell	12032025	292.98	100	29,298	2,465,720	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Wilder, Thomas		Direct	Sell	1062026	310.72	186			Form
2	Bose, Arani		LLC	Sell	12152025	308.82	15,000	4,632,292	79,818,099	Form
3	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	12092025	300.13	300	90,039	19,159,099	Form
4	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	12032025	294.94	600	176,966	18,916,497	Form
5	Grewal, Harpreet		Direct	Sell	12032025	292.98	100	29,298	2,465,720	Form
6	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	11262025	300.06	1,800	540,108	19,424,684	Form
7	Bose, Arani		LLC	Sell	11262025	300.19	7,500	2,251,425	82,630,600	Form
8	Bose, Arani		LLC	Sell	11252025	290.56	7,500	2,179,212	82,159,507	Form
9	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	11122025	266.98	600	160,189	16,995,213	Form
10	Grewal, Harpreet		Direct	Sell	11062025	227.58	186	42,330	1,938,071	Form
11	Grewal, Harpreet		Direct	Sell	10032025	248.61	186	46,241	2,163,404	Form
12	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	10032025	249.70	600	149,820	16,045,016	Form
13	Wilder, Thomas		Direct	Sell	10032025	253.93	186	47,231	47,231	Form
14	Grewal, Harpreet		Direct	Sell	9042025	272.19	186	50,627	2,419,225	Form
15	Elsesser, Adam	CEO	Direct	Sell	9042025	269.65	15,800	4,260,457	49,200,188	Form
16	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	9042025	270.58	600	162,347	17,548,904	Form
17	Elsesser, Adam	CEO and President	Direct	Sell	8222025	254.53	15,900	4,046,952	43,340,568	Form
18	Yuen, Maggie	Chief Financial Officer	Direct	Sell	8152025	250.00	2,000	500,000	3,235,750	Form
19	Bose, Arani		Direct	Sell	8152025	250.65	12,000	3,007,776	139,862	Form
20	Wilder, Thomas		Direct	Sell	8132025	240.16	372	89,340	89,340	Form
21	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	8132025	238.94	600	143,363	15,640,214	Form
22	Elsesser, Adam	CEO and President	Direct	Sell	8082025	238.20	16,030	3,818,363	37,684,361	Form
23	Elsesser, Adam	CEO and President	Direct	Sell	7252025	233.16	16,150	3,765,574	34,101,880	Form
24	Elsesser, Adam	CEO and President	Direct	Sell	7112025	243.75	15,985	3,896,344	32,767,804	Form
25	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	7032025	252.70	600	151,622	16,692,786	Form
26	Elsesser, Adam	CEO and President	Direct	Sell	6272025	253.40	15,890	4,026,589	31,027,032	Form
27	O'Rourke, Bridget		Direct	Sell	6182025	259.78	50	12,989	1,395,798	Form
28	Elsesser, Adam	CEO and President	Direct	Sell	6132025	253.67	15,910	4,035,890	27,993,752	Form
29	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	6042025	258.17	600	154,903	16,707,344	Form
30	Elsesser, Adam	CEO and President	Direct	Sell	5302025	267.91	16,300	4,366,920	26,332,526	Form
31	Elsesser, Adam	CEO and President	Direct	Sell	5162025	298.22	16,600	4,950,476	25,829,853	Form
32	O'Rourke, Bridget		Direct	Sell	5162025	286.15	100	28,615	1,551,791	Form
33	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	5142025	298.55	900	268,698	19,499,684	Form
34	Elsesser, Adam	CEO and President	Direct	Sell	5092025	289.37	16,650	4,818,006	21,771,312	Form
35	Yuen, Maggie	Chief Financial Officer	Direct	Sell	5062025	299.01	2,000	598,020	4,173,283	Form
36	Bose, Arani		Direct	Sell	4292025	298.73	12,000	3,584,775	90,461,501	Form
37	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	4252025	300.01	600	180,006	19,848,362	Form
38	Elsesser, Adam	CEO and President	Direct	Sell	4182025	274.35	16,560	4,543,228	17,533,953	Form
39	O'Rourke, Bridget		Direct	Sell	4172025	271.21	50	13,560	1,497,893	Form
40	Elsesser, Adam	CEO and President	Direct	Sell	4042025	272.24	16,565	4,509,728	14,291,469	Form
41	Wilder, Thomas		Trust	Sell	4042025	266.93	360	96,095	1,252,436	Form
42	Wilder, Thomas		Trust	Sell	4022025	264.58	360	95,249	1,199,341	Form
43	Roberts, Johanna	EVP, Gen. Counsel & Secretary	Direct	Sell	4022025	269.11	600	161,466	17,856,272	Form
44	Grewal, Harpreet		Direct	Sell	4022025	267.17	200	53,434	2,424,301	Form
45	Yuen, Maggie	Chief Financial Officer	Direct	Sell	3042026	342.30	2,432	832,474	6,282,232	Form
46	Grewal, Harpreet		Direct	Sell	4062026	328.22	100	32,822	2,861,750	Form

PEN Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing PEN?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What PEN Makes & Who Pays

TTM figures based on

PEN Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Penumbra (PEN)

Market Price (4/12/2026): $329.82 | Market Cap: $12.9 BilSector: Health Care | Industry: Health Care Equipment

Penumbra (PEN)

Market Price (4/12/2026): $329.82Market Cap: $12.9 BilSector: Health CareIndustry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Penumbra (PEN)

Expected Drivers of Future Revenue Growth for Penumbra (PEN)

Expansion and Innovation in Computer Assisted Vacuum Thrombectomy (CAVT) Portfolio

International Market Expansion

Growing Adoption of U.S. Thrombectomy and Embolization Products

Positive Clinical Data Driving Product Adoption

Interactive Breakdown

Better Bets vs. Penumbra (PEN)

INDUSTRY: Health Care Equipment

Higher Rev Chg 3Y Avg | Lower P/S (Values for PEN: 18.4% | 9.2x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for PEN: 18.4% | 68.3x)

Higher Rev Chg LTM (Value for PEN: 17.5%)

Higher Rev Chg 3Y Avg (Value for PEN: 18.4%)

Higher Op Mgn LTM (Value for PEN: 13.5%)

Higher CFO/Rev LTM (Value for PEN: 17.0%)

Higher FCF/Rev LTM (Value for PEN: 12.5%)

Higher Total Yield (Value for PEN: 1.4%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for PEN: 18.4% | 9.2x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for PEN: 18.4% | 68.3x)

Higher Rev Chg LTM (Value for PEN: 17.5%)

Higher Rev Chg 3Y Avg (Value for PEN: 18.4%)

Higher Op Mgn LTM (Value for PEN: 13.5%)

Higher CFO/Rev LTM (Value for PEN: 17.0%)

Higher FCF/Rev LTM (Value for PEN: 12.5%)

Higher Total Yield (Value for PEN: 1.4%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for PEN: 18.4% | 9.2x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for PEN: 18.4% | 68.3x)

Higher Rev Chg LTM (Value for PEN: 17.5%)

Higher Rev Chg 3Y Avg (Value for PEN: 18.4%)

Higher Op Mgn LTM (Value for PEN: 13.5%)

Higher CFO/Rev LTM (Value for PEN: 17.0%)

Higher FCF/Rev LTM (Value for PEN: 12.5%)

Higher Total Yield (Value for PEN: 1.4%)

Best Bets in Health Care

P/EBIT (Value for PEN: 62.6x)

P/E (Value for PEN: 72.7x)

Rev Chg 3Y Avg (Value for PEN: 18.4%)

Rev Chg LTM (Value for PEN: 17.5%)

Rev Chg Q (Value for PEN: 22.1%)

FCF/Rev 3Y Avg (Value for PEN: 10.9%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Market Price (4/12/2026): $329.82 | Market Cap: $12.9 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (4/12/2026): $329.82
Market Cap: $12.9 Bil
Sector: Health Care
Industry: Health Care Equipment